Point-of Care Ultrasound for Patients With HIV

Sponsor
Erasmus Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04246983
Collaborator
(none)
37
1
1
26
1.4

Study Details

Study Description

Brief Summary

Rationale: Point-of-care ultrasound (POCUS) is increasingly used by various specialists in the Netherlands, but its role in managing patients with HIV is unclear. In settings endemic for tuberculosis, Fast Assessment with Sonography for HIV/Tuberculosis (FASH) has proven its value to detect extrapulmonary tuberculosis in patients with HIV. However, there is no data to support POCUS for patients with HIV in resource affluent settings.

Objective: The investigators aim to determine the feasibility and diagnostic value of POCUS in detecting opportunistic disease in HIV patients with advanced disease stages in the Netherlands.

Study design: The investigators will perform a prospective observational pilot study.

Study population: The investigators will include new adult patients with HIV presenting with a cluster of differentiation 4 (CD4) T-cell count below 350 cells/mm3, and all adult HIV patients requiring admission to hospital. Intervention (if applicable): The investigators will perform a focused ultrasound examination including FASH, and ultrasound of the lung, liver and kidneys. In case of positive findings additional examinations will be undertaken to determine the underlying pathology and/or treatment started as indicated. In case of negative findings, patients will be followed for 12 months to observe for (possibly missed) opportunistic infections.

Main study parameters/endpoints: Our primary outcomes include acceptability of POCUS by patients, interobserver variation in interpretation of POCUS images, and number of diagnosed AIDS and non-AIDS related problems. Secondary outcomes include sensitivity and specificity, negative predictive value and positive predictive value of our POCUS protocol. In addition, incidence rates of opportunistic infections will be compared to a historical matched control group.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The ultrasound examination is painless and without risk to the participants. It will take approximately 30 minutes and will be combined with routine visits to the hospital. Benefits include potential earlier detection of opportunistic disease, while adverse effects may arise from false positive findings requiring further examinations which may cause stress or anxiety. The rate of false positive findings in POCUS has not been formally investigated, but appears low. The effect of POCUS in advanced HIV/AIDS can only be studied in HIV patients.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Opportunistic infection Ultrasound (OpUS) screening
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
37 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Introducing Point-of-care Ultrasound at the Bedside for Diagnosing Opportunistic Diseases in Patients With HIV
Actual Study Start Date :
Jul 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with HIV undergoing point of care ultrasound

Diagnostic Test: Opportunistic infection Ultrasound (OpUS) screening
this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.

Outcome Measures

Primary Outcome Measures

  1. Acceptance rate of point-of-care ultrasound by patients [1 day]

  2. interobserver variation in interpretation of ultrasound images [1 day]

  3. Number of diagnosed AIDS and non-AIDS related problems [1 year]

Secondary Outcome Measures

  1. Sensitivity and specificity, negative predictive value and positive predictive value of our ultrasound protocol to diagnose opportunistic disease. [1 year]

  2. Number of diagnosed AIDS and non-AIDS related problems compared to a historic control group [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • new patients with HIV presenting with a CD4 T-cell count below 350 cells/mm3

  • patients with HIV who are admitted to hospital

Exclusion Criteria:
  • absence of informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Erasmus MC Rotterdam Netherlands

Sponsors and Collaborators

  • Erasmus Medical Center

Investigators

  • Principal Investigator: Mischa Huson, MD, PhD, Erasmus Medical Centre

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mischa Huson, Principal Investigator, Erasmus Medical Center
ClinicalTrials.gov Identifier:
NCT04246983
Other Study ID Numbers:
  • NL72666.078.20
First Posted:
Jan 29, 2020
Last Update Posted:
Jul 23, 2020
Last Verified:
Jul 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mischa Huson, Principal Investigator, Erasmus Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 23, 2020